MA51337A - Inhibiteurs spiro exo-aza de l'interaction ménine-mll - Google Patents

Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Info

Publication number
MA51337A
MA51337A MA051337A MA51337A MA51337A MA 51337 A MA51337 A MA 51337A MA 051337 A MA051337 A MA 051337A MA 51337 A MA51337 A MA 51337A MA 51337 A MA51337 A MA 51337A
Authority
MA
Morocco
Prior art keywords
menin
exo
spiro
mll interaction
aza
Prior art date
Application number
MA051337A
Other languages
English (en)
Inventor
Patrick René Angibaud
Wei Cai
Xuedong Dai
James Patrick Edwards
Liqiang Fu
Linglong Kong
Daniel Jason Krosky
Yingtao Liu
Geb Herkert Barbara Morschhäuser
Vineet Pande
Aaron Nathaniel Patrick
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Zhao-Kui Wan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA51337A publication Critical patent/MA51337A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
MA051337A 2017-12-20 2018-12-19 Inhibiteurs spiro exo-aza de l'interaction ménine-mll MA51337A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017117536 2017-12-20
CN2018091521 2018-06-15

Publications (1)

Publication Number Publication Date
MA51337A true MA51337A (fr) 2020-10-28

Family

ID=66993097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051337A MA51337A (fr) 2017-12-20 2018-12-19 Inhibiteurs spiro exo-aza de l'interaction ménine-mll

Country Status (12)

Country Link
US (1) US20230039917A1 (fr)
EP (1) EP3728260A4 (fr)
JP (1) JP7307729B2 (fr)
KR (1) KR20200101389A (fr)
CN (1) CN111601807B (fr)
AU (1) AU2018389145B2 (fr)
BR (1) BR112020012461A2 (fr)
CA (1) CA3083624A1 (fr)
IL (1) IL275457A (fr)
MA (1) MA51337A (fr)
MX (1) MX2020006594A (fr)
WO (1) WO2019120209A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110950818B (zh) * 2019-12-18 2021-12-28 浙江海翔药业股份有限公司 顺式-2,6-二甲基吗啉的纯化方法
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
TW202302565A (zh) * 2021-02-19 2023-01-16 英商卡爾維斯塔製藥有限公司 酶抑制劑
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
EP4334320A1 (fr) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Dérivés spiro substitués
WO2022241265A1 (fr) * 2021-05-14 2022-11-17 Syndax Pharmaceuticals, Inc. Inhibiteurs de l'interaction ménine-mll

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505781B2 (en) 2013-03-13 2016-11-29 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
JP2018538330A (ja) * 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
WO2017207387A1 (fr) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Dérivés d'azétidine spiro condensés en tant qu'inhibiteurs de l'interaction ménine-mml1
CA3024180A1 (fr) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibiteurs de l'interaction menine-mll
EA201990699A1 (ru) * 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
US11396517B1 (en) * 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction

Also Published As

Publication number Publication date
US20230039917A1 (en) 2023-02-09
CN111601807B (zh) 2023-03-31
BR112020012461A2 (pt) 2020-11-24
AU2018389145A1 (en) 2020-05-21
RU2020123548A3 (fr) 2022-02-17
RU2020123548A (ru) 2022-01-20
EP3728260A4 (fr) 2021-08-11
EP3728260A1 (fr) 2020-10-28
IL275457A (en) 2020-08-31
KR20200101389A (ko) 2020-08-27
JP2021506882A (ja) 2021-02-22
AU2018389145B2 (en) 2023-02-02
JP7307729B2 (ja) 2023-07-12
WO2019120209A1 (fr) 2019-06-27
CA3083624A1 (fr) 2019-06-27
MX2020006594A (es) 2020-09-09
CN111601807A (zh) 2020-08-28

Similar Documents

Publication Publication Date Title
IL283267A (en) Inhibitors of menin–mll interaction
MA46228A (fr) Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MA52814A (fr) Inhibiteurs de bromodomaine
MA47573A (fr) Inhibiteurs de dihydrobenzofurane glycosidase substitués
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA46180A (fr) Analogues de l'amyline
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
DK3430143T3 (da) Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA49006A (fr) Inhibiteurs d'ip6k
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
MA51611A (fr) Inhibiteurs de pi4kiiibêta
MA52809A (fr) Inhibiteurs de sarm1
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
ITUA20161994A1 (it) Uso degli inibitori ddx3 come agenti anti-iperproliferativi
FI20160028A (fi) Tolpan perustus
MA50034A (fr) Composition de stimulation ovarienne contrôlée
DK3377061T3 (da) Mirabegron til behandling af nethindesygdomme
UA40596S (uk) Набір упаковок